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Abstract
A new MPA assay based on the enzymatic activity of recombinant IMPDH II (the pharmacological target of MPA) with excellent
correlation with HPLC has recently been released for the measurement of MPA plasma levels. This study aimed to: (i) compare this
new assay with LC-MS/MS for MPA pharmacokinetic studies in different populations of allograft recipients given mycophenolate
mofetil (MMF); (ii) develop specific Bayesian estimators for this inhibition assay and test their accuracy; and (iii) compare the
resulting MPA area under the curve (AUC ) estimates with those of Bayesian estimators developed based on the LC-MS/MS0 12h –
results.
Sixty-four adult or pediatric, renal or lung transplant patients who were administered MMF in association with cyclosporine,
tacrolimus or sirolimus at different post-transplant periods were enrolled as part of different PK studies. 894 patients  samples were’
analyzed in parallel with the enzymatic MPA assay and a reference LC-MS/MS method. Repeated analysis of quality control samples
showed a mean difference of 6  between the two assays, while the results obtained in different populations of transplanted patients%
showed excellent correlation (r > 0.96) and small mean relative differences (2.0 to 16.9 ). The full profiles obtained with both assays2 %
were adequately fitted using either a two-compartment model with one gamma  absorption phase, or a one-compartment model with“ ”
two gamma inputs. Several PK parameters were significantly affected by the analytical method used. Accurate Bayesian estimators
could be specifically developed for the enzymatic MPA assay, using the same three concentration-time points (20 min, 1h, 3h
post-dose) as with LC-MS/MS, with a median bias versus reference (trapezoidal) AUC values of 1.3  (range 45.2 to 40.4 ) and0 12h – − % − %
83  of the patients within  20  of the reference. These Bayesian estimates were significantly higher than those obtained with% ± %
LC-MS/MS in patients on cyclosporine or sirolimus, but not in patients on tacrolimus.
MESH Keywords Adult ; Anti-Bacterial Agents ; pharmacokinetics ; Child ; Cyclosporine ; pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Interactions ; 
Female ; Graft Survival ; immunology ; Humans ; Immunosuppressive Agents ; pharmacokinetics ; Kidney Transplantation ; Male ; Mycophenolic Acid ; analogs & derivatives ; 
pharmacokinetics ; Sirolimus ; pharmacokinetics ; Tacrolimus ; pharmacokinetics ; Transplantation, Homologous
Author Keywords mycophenolic acid ; monitoring ; enzymatic assay ; LC-MS/MS ; Bayesian estimators.
Introduction
Mycophenolate (MPA) is an antiproliferative agent that acts by uncompetitive, reversible and selective inhibition of type II inosine
monophosphate dehydrogenase (IMPDH II), a key enzyme in the biosynthesis of purines ( ). MPA is metabolized byde novo 1 
glucuronidation primarily to MPA-phenyl-glucuronide (MPAG), which is pharmacologically inactive ( ), as well as to the presumably2 
toxic MPA-acyl-glucuronide (AcMPAG) ( ). A wide interpatient and intrapatient variability was reported for MPA pharmacokinetics (3 –5 
), leading to the recommendation of therapeutic drug monitoring of mycophenolate mofetil, preferably based on MPA inter-dose area6 –8 
under the concentration-time curve (AUC ) ( , ).0 12h – 9 10 
However, differences in analytical techniques were found to affect plasma MPA measurement. Previous comparative studies between
the enzyme-multiplied immunoassay technique (EMIT, Dade-Behring) and LC-MS/MS ( , ) for the determination of mycophenolate11 12 
(MPA) in renal transplant patients showed that: when mycophenolate mofetil (MMF) was associated with cyclosporine, EMIT
significantly overestimated MPA levels in clinical samples (mean 61.4 , SD 57.94 ; median 46.51 , range 27.7 to 422.8 ), with+ % % % − + %
large variations depending on patients, time elapsed since transplantation, sampling time and concentration levels ( ); when MMF was11 
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combined with sirolimus, the EMIT kit gave a significant but lesser overestimation of 18.7  26.8  as compared to LC-MS/MS, also with± %
variations depending on post-transplantation periods ( ). Therefore HPLC-UV and LC-MS/MS have so far been the standard12 
technologies used for MMF therapeutic drug monitoring. Roche Diagnostics designed and recently released a new MPA assay based on
the enzymatic activity of recombinant IMPDH (the pharmacological target of MPA), the Roche (called herein Mycophenolic Acid assay  ™
enzymatic MPA assay ), which was recently shown to precisely measure total MPA plasma levels in the range of 0.31 to 15 mg/l with‘ ’
excellent correlation with HPLC and LC-MS/MS methods and only 5  cross-reactivity with AcMPAG, though it tended to overestimate%
MPA concentrations near the quantification limit ( ).13 
A multi-centre, randomized, prospective trial in 137 renal transplant recipients showed that MMF dose adjustment based onde novo 
MPA AUC resulted in significantly less rejections in the first year post-transplantation ( ). This clinical trial was conducted using0 12h – 14 
pharmacokinetic models and Bayesian estimators specifically set up for plasma MPA levels as determined using HPLC ( , ), which15 16 
are now available on the ISBA (ImmunoSuppressants Bayesian Adjustment) website (at ) ( ).https://pharmaco.chu-limoges.fr/abis.htm 17 
The larger, comparative, randomized FDCC trial did not show significant differences between the concentration-controlled and the
fixe-dose arms, but the renal transplant patients were much more diverse (adults and pediatrics, on cyclosporine or tacrolimus, with MPA
measurements made by HPLC or EMIT) and the tools used for dose adjustment (i.e., multilinear regression equations) were probably not
as robust and accurate as Bayesian estimation ( ). On top of that, physician s compliance with dose adjustment proposals was only 5218 ’ %
in FDCC ( ), versus 85  on average in the smaller trial ( ).18 % 14 
The aims of the present study were: (i) to further evaluate the enzymatic MPA assay as compared to a reference LC-MS/MS technique
for MPA pharmacokinetic studies in different populations of allograft recipients given MMF; (ii) to develop specific Bayesian estimators
for this enzymatic MPA assay and test their accuracy; and (iii) to compare the resulting MPA AUC estimates with those of Bayesian0 12h –
estimators developed for LC-MS/MS in the same patients  groups.’
Material & methods
Patients and samples
Plasma samples were collected from 64 patients who gave their informed consent to participate in one of various pharmacokinetic
studies approved by regional ethic committees and authorized by the Agence Fran aise de S curit  Sanitaire des Produits de Sant , theç é é é
French Drug Agency. Sampling times ranged from pre-dose to 6 12 h post-dose, at post-transplant periods varying from day 7 to several–
years. Twenty profiles came from 20 pediatric renal transplant recipients on cyclosporine (beyond one year post-transplantation), 16
profiles from 10 adult renal transplants on cyclosporine (10 early, i.e. within the first three months post-transplant, and 6 late  or stable -–
periods), 30 profiles from 10 adult renal transplants on tacrolimus (collected at D7, M1 and M3), 28 profiles from 14 adult renal
transplants on sirolimus (stable post-transplant periods) and 14 profiles from 10 adult lung transplants on tacrolimus (early and stable
post-transplant periods).
All samples were kept frozen for a period of time ranging from 2 months to 2 years before the comparison study.
Analytical methods
The enzymatic MPA assay, based on a two-reagent system, was run on a COBAS INTEGRA 400 system. After sample addition to the
reaction mixture, MPA in the sample inhibits IMPDH II that normally catalyzes the conversion of IMP (inosine monophosphate) and NAD
(nicotinamide adenine dinucleotide) to XMP (xanthosine monophosphate) and NADH. The enzymatic reaction is monitored by measuring
the rate of NADH formation at 340 nm ( ). MPA concentration is inversely proportional to the rate of NADH formation. The measuring13 
range used in this study was 0.4 to 15 mg/L. Using control samples for total MPA at three levels (0.8, 3.5 and 12 mg/L), the intra-assay
CV  was 1.0 , 0.6  and 1.1 , respectively (n  21).% % % % =
The LC-MS/MS technique employed was previously described in detail ( ). Briefly, to 100 L of plasma were added 50 L of11 μ μ
indomethacin (internal standard) at 50 mg/L and 250 L of a mixture of acetonitrile and 99  pure formic acid (97/3, v/v). Afterμ %
vortex-mixing and centrifugation, 3 L of the supernatant were injected into a Nucleosil C , 5 m (150  1 mm ID.) column. The mobileμ 18 μ ×
phase, delivered at a flow-rate of 50 L.min , was a gradient of acetonitrile in 5mmol/L, pH 3.0 ammonium formate. Detection wasμ 1 −
performed using a 2000 Q-TRAP tandem mass-spectrometer (Applied-Biosystems/Sciex, Foster, CA, USA) in the negative ion, multiple
reaction monitoring mode using the following transitions: MPA (m/z 319  191 for quantification and m/z 319  275 for− → − − → −
confirmation) and indomethacin (m/z 356  312 for quantification and m/z 356  297 for confirmation). The limit of detection was− → − − → −
0.05 mg/L and the limit of quantitation (LLOQ) 0.1 mg/L. Linearity was verified up to 30 mg/L (r  0.999). The within-day and=
between-day precision (CV  < 10  and < 15 , respectively) and accuracy (mean bias < 7  for both) were satisfactory over the% % % %
calibration range. Samples with MPA concentration > 30 mg/L (upper limit of quantitation) were diluted 1/2 with blank human plasma and
re-analyzed.
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Method comparison
The three QC samples provided by Roche Diagnostics for the enzymatic MPA assay and two commercial QC samples for MPA
monitoring (ChromSystems, level I: 1.8 mg/L; and level II: 4.86 mg/L) were analyzed with each batch of patients  samples using both’
assays, for cross-checking.
Furthermore, six external quality control samples from the International Mycophenolate Proficiency Testing Scheme (3 pools of blank
plasma spiked to a known concentration of MPA and 3 pools of plasma from treated patients) were purchased from Analytical Services
International (London, UK) in sufficient volumes and analyzed by both methods with 15 different batches of patients  samples.’
Patients  plasma samples were thawed in batches and analyzed in parallel, on the same day, with both methods. For the enzymatic’
MPA assay, samples with MPA concentration above 15 mg/L (upper limit of quantitation) were diluted 1/4 with blank human plasma and
re-analyzed.
PK modeling and development of Bayesian estimators
Two previously published PK models able to fit MPA absorption profiles were tested ( ): a two-compartment open model with first15 
order elimination and a single gamma input to describe the absorption phase; and a one-compartment open model with first order
elimination and a sum of two gamma distributions to describe the absorption phase, theoretically able to describe the double-peak
concentration-time curves frequently observed with MPA.
Population parameters were estimated using the iterative 2-stage method (ITS) as implemented in an in-house computer program.
Bayesian fitting of the PK model to each individual data set (all available concentrations) employed the simplex algorithm to minimize the
individual objective function value:
where C denotes an observed concentration, S its standard deviation, E the corresponding theoretical concentration,  the vector ofi i i θ
fitted parameters,  the mean parameter values in the reference population, and the inverse variance-covariance matrix. The symbol Tμ Σ 1 −
denotes matrix transposition. The calibration experiments showed that S could be expressed as a power function: S  0.015 C , wherei i = × i 1.2 
C and S are in mg/L. The program used the individual parameter estimates together with their variance-covariance matrix to generate ai i 
new set of population parameter estimates. These population estimates were then used as Bayesian priors and refined by successive
population iterations until convergence.
For each PK profile, the two PK models (i.e., the two-compartment model with one gamma law and the one-compartment model with
two gamma laws) were applied and the best one was selected based on the lowest Akaike criterion ( ), calculated as follows:19 
where is the value of the objective function at minimum and p the number of parameters in the model.Φmin 
Using the appropriate pharmacokinetic model and the final set of population parameter estimates (mean, standard deviation and
correlation matrix), maximum a posteriori Bayesian estimators (MAP-BE) were developed as previously described ( , ), for each16 20 
group of patients defined by the associated immunosuppressant and post-transplantation period. Every combination of 3 sampling times
within the first 3 hours post-dose was tested for MAP-Bayesian forecasting.
Statistical analyses
Method comparison was performed globally, as well as separately for the different sub-populations. Correlation analysis was
conducted using the non-parametric Passing-Bablok method ( ). The relative difference was calculated as (enzymatic MPA21 
assay-LC-MS/MS)/LC-MS/MS, and normalized relative difference as (enzymatic MPA assay-LC-MS/MS)/mean (enzymatic MPA assay
and LC-MS/MS).
For each individual post-transplantation period, the best limited sampling strategies (LSS) for Bayesian estimation were selected on
the basis of: (i) the best squared correlation coefficients (r ); and (ii) the lowest bias between observed and estimated AUC (AUC2 0 12h –
being the main index targeted). Then, for practical reasons, a common LSS over the 3 periods was sought and evaluated. The whole
procedure was repeated for MPA PK profiles generated using the enzymatic MPA assay and LC-MS/MS.
The influence of age, transplanted organ, associated drug and post-transplantation period on the relative differences between the two
techniques was tested using one-way ANOVA, then two-by-two comparisons for the influence of the associated immunosuppressive drug
by the Scheffe test.
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Finally, the PK parameters obtained with the enzymatic MPA assay and LC-MS/MS at different post-transplantation periods on the
one hand, and the respective Bayesian AUC estimates on the other hand were compared using paired t-tests.0 12h –
All statistic analyses were performed using Statview 5.0 (SAS Institute Inc., USA).
Results
The cross-checking of internal quality control samples analyzed routinely with the batches of patients  samples showed that there was’
no systematic difference between the enzymatic MPA assay and LC-MS/MS and that the inter-assay CVs obtained with the former were
always less than those obtained with the latter ( ). Moreover, repeated analysis (15 or 16 replicates) of spiked or patients  samplestable I ’
from the Mycophenolate International Proficiency Testing Scheme showed a mean difference  6  between the two assays and lower CV≤ %
 values with the enzymatic MPA assay than with LC-MS/MS, except for the spiked sample at the highest concentration ( ). The% table II 
MPA concentrations as measured by LC-MS/MS in 894 patients samples taken over dosing intervals ranged between BLOQ (i.e., below
0.1 mg/L) and 33.4 mg/L. The concentration measured by the enzymatic MPA assay was lower than 0.4 mg/L, limit of quantitation of the
assay, in 29 samples. When comparing the results obtained for the remaining 865 patients  samples, the mean overestimation of the’
enzymatic MPA assay was 7.8 12.7  (median 7 , range 19.1 to  54.5 ), translating into mean  6.8 11.7  (median 6.8 , range %± % % − + % = %± % % −
21.2 to  42.8 ) for the normalized relative difference (enzymatic MPA assay  LC-MS/MS)/mean (enzymatic MPA assay and+ % –
LC-MS/MS), with r  0.9839 and more than 95  samples within 20  to 30  ( ).= % − % + % figure 1 
Though samples above 15 mg/L (n  47) were determined with the same accuracy and precision after dilution with blank plasma as=
samples in the linearity range ( ), method comparison within the different sub-groups defined by age, transplanted organ,figure 1 
co-administered immunosuppressant and post-transplantation period ( ) were limited to the 818 samples with concentration valuestable III 
within the linearity range of the enzymatic MPA assay (0.4 to 15 mg/L), in order to avoid sample dilution as a confusing factor. They
showed that the agreement between the two methods was excellent in all cases, with slightly though significantly higher overestimation of
the enzymatic MPA assay in adults than in children, in patients on cyclosporine than in those on tacrolimus or sirolimus, and in the stable
than in the early (i.e., within the first three months) post-transplantation periods ( ). In contrast, there was no significant differencetable III 
between lung- and kidney transplant recipients.
In the study database, 68 PK profiles containing at least 10 concentration-time points could be used to develop PK models and
Bayesian estimators. These PK profiles analyzed with both the enzymatic MPA assay and the LC-MS/MS technique were adequately fitted
using the same types of PK models as those previously reported for MPA ( ), though with a different equation for the analytical error,16 
specifically calculated from the assay validation data. In the vast majority of cases, the one-compartment open model with two gamma
laws (i.e., two peaks) best fitted the profiles in the early post-transplantation period and the two-compartment open model with one gamma
law (i.e., one peak) those in the stable post-transplantation period. Considering this database (n  668 and 743 concentration values for=
LC-MS/MS and for the enzymatic MPA assay, respectively), excellent correlation was found between observed and modelled MPA
plasma concentrations (r  0.93 for both methods). However, significant differences in the PK parameter values were found between the2 =
models developed for the enzymatic MPA assay and those for LC-MS/MS in patients on cyclosporine: 1 out of 7 parameters in the stable
post-transplantation period (namely C0; model with one peak) and 4 out of 8 parameters in the early post-transplantation phase (namely
C0, a1, a2 and b2; model with two peaks) were significantly different between the two techniques (p<0.01). No significant difference was
found in patients on sirolimus or tacrolimus.
Using these PK models, specific Bayesian estimators were then developed for accurate estimation of MPA AUC as measured with0 12h –
the enzymatic MPA assay, as well as with LC-MS/MS in the same groups of patients. The best sampling strategy over the different
post-transplantation periods and across transplant groups comprised three time points at 20 min, 1h and 3h post-dose, for both analytical
techniques.
For the enzymatic MPA assay, depending on the post-transplantation period and concomitant immunosuppressive drug, the median
bias of the Bayesian versus reference (trapezoidal) AUCs was 1.3  (range 45.2 to 40.4 ), with 83  of the patients with AUC bias <− % − % %
20  ( ). Examples of concentration-time profiles of MPA measured using the enzymatic MPA assay and estimated using the% figure 2 
Bayesian method and the 20 min-1h 3h limited sampling schedule are shown in . The relative difference in AUC estimates– figure 3 
obtained using the enzymatic MPA assay or LC-MS/MS was 12.3  15.3  on average. The individual relative differences were highest± %
and significant in patients given cyclosporine (13.3  20.4 ; p<0.01), moderate and still significant in those on sirolimus (10.1  10.8 ;– % – %
p<0.01), lower and not significant in patients given tacrolimus (4.1  9.1 ; n.s). shows the Bland-Altman ( ) representation of– % Figure 4 22 
these relative differences.
Discussion
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The new enzymatic MPA assay tested showed excellent correlation with LC-MS/MS for the determination of total MPA in plasma of
adult or pediatric, renal or lung transplant patients under cyclosporine, tacrolimus or sirolimus in the early or stable post-transplantation
periods. A negligible systematic bias of about 6  was found between the two techniques when analysing spiked plasma samples+ %
routinely, with the enzymatic MPA assay showing better precision.
Full PK profiles may result in very low (down to 0.017 mg/L) to quite high (up to 33.4 mg/L) plasma levels, some of which were out
of the analytical range of the enzymatic MPA assay. However, very low concentrations were mainly found for trough levels obtained very
early after transplantation, when it is now widely accepted that trough levels have limited significance, at least for MMF dose adjustment (
). In the present as well as in previous studies ( , , ), we proposed Bayesian estimators of MPA AUC based on plasma10 14 16 17 0 12h –
samples collected at approx. 20 min, 1h and 3h post-dose, times at which MPA plasma levels were almost always above the LLOQ of the
enzymatic MPA assay in our hands (0.4 mg/L). Above this LLOQ, the enzymatic MPA assay gave results very close to those of
LC-MS/MS in all patients groups as determined by age, transplanted organ, co-administered immunosuppressant and post-transplantation
period, though with slight overestimation of MPA plasma levels in patients on cyclosporine (mean 10.7 ). This last finding is in%
agreement with those of previous reports comparing EMIT to LC-MS/MS, which showed that EMIT overestimated MPA plasma levels
more in patients co-administered cyclosporine ( ) than sirolimus ( ) or tacrolimus ( , ), although overestimation was then globally11 12 23 24 
much higher with EMIT than with the enzymatic MPA assay herein. This might be due to the inhibition of the biliary excretion of MPA
phase II metabolites, by cyclosporine but not tacrolimus or sirolimus ( ), resulting in an increase in plasma concentrations of these25 –27 
metabolites, mainly AcMPAG. However, it was shown that MPAG did not inhibit IMPDH, while MPA-acyl-glucuronide (AcMPAG)
exhibited only 5  of MPA inhibition activity on the recombinant enzyme when incubated alone ( ), and even less when co-incubated% 13 
with MPA ( ). However, the overestimation of actual MPA levels by the enzymatic MPA assay found in patients on cyclosporine should28 
be of little clinical significance, so much so that this overestimation is proportional across the linearity range and with time post-dose,
contrary to that of EMIT ( ). It should also be noted that a previously published inter-laboratory validation of the enzymatic MPA assay,11 
which was conducted after the present study and in which we also participated, found no significant overestimation, whether in patients on
cyclosporine or on tacrolimus ( ). This could be due to the nature of the kit itself, as the beta-version used in the present study was13 
slightly different from the commercial version employed in the interlaboratory validation study.
Two different PK models with either one or two gamma laws, previously developed for renal transplant patients ( ) were used to fit15 
the present database. As raw data showed that patients could exhibit PK profiles with either one or two peaks, the best model was selected
for each profile based on the Akaike criterion (a selection procedure now automatically applied to all three-point profiles sent to the ISBA
website).
Significant differences in the PK parameters were found between LC-MS/MS and the enzymatic MPA assay, highlighting that
analytical techniques not only impact the actual levels measured and the residual error of the models, but also the distribution of PK
parameters in the population. This advocates the need for specific (or possibly adapted) models for pharmacokinetically-guided TDM
when different analytical techniques are employed, even when they give close results as in the present study.
Bayesian estimators derived from these models were able to accurately estimate MPA AUCs when measured with the enzymatic MPA
assay (i.e., more than 80  of the AUC estimates were within  20  of the actual values), with similar efficiency at all post-transplantation% ± %
periods and for all three associated immunosuppressive drugs. When comparing Bayesian AUC estimates to those obtained with
LC-MS/MS, significant although limited mean differences were observed, mainly in patients on cyclosporine or sirolimus. Also, the
distribution of the AUC relative differences with respect to LC-MS/MS ( ) was very similar to that of the raw concentration data (figure 4 
). This should not be of clinical significance, in as much as the commercial enzymatic MPA assay apparently presents lessfigure 1 
overestimation than the beta version used in the present study (see above). This should not affect the accuracy of the Bayesian estimators
developed here, which are more sensitive to curve shapes (hence PK parameters) than to absolute concentration values.
These tools were added to the ISBA website (https://pharmaco.chu-limoges.fr/abis.htm) to allow dose adjustment of MMF when
measured using the Roche Diagnostics total MPA kit and have been used successfully since.
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Figure 1
Comparison of the Roche enzymatic MPA assay run on the COBAS INTEGRA system with LC-MS/MS using plasma samples with MPA
concentration > 0.4 mg/L, as determined by the enzymatic MPA assay. A) Passing-Bablok correlation analysis. B) Normalized relative
differences (i.e., (enzymatic MPA assay  LC-MS/MS)/mean of (enzymatic MPA assay and LC-MS/MS) plotted against increasing mean–
concentration, as represented by sequence number.
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Figure 2
Bias of the Bayesian estimates of MPA AUC obtained using the 20 min-1h 3h sampling schedule with respect to the true , trapezoidal0 12h – – “ ”
AUC sorted out by: A) associated immunosuppressant; and B) post-transplantation periods.0 12h –
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Figure 3
Examples of concentration-time profiles of MPA measured using the enzymatic MPA assay and estimated using the Bayesian method and the
20 min-1h 3h sampling schedule. A) Profile obtained early after transplantation in a patient given tacrolimus, showing a double plasma–
concentration peak. B) Profile obtained in a stable patient given cyclosporine, with no second concentration peak.
Figure 4
Bland-Altman representation of the relative bias of MPA Bayesian estimates obtained using concentrations measured at approx. 20 min, 1h
and 3h post-dose with the enzymatic MPA assay as compared to LC-MS/MS.
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Table I
Cross-checking of internal quality controls analysed using the enzymatic MPA assay and LC-MS/MS in parallel.
Method IQC sample Target (mg/L) N = Median concentration (range) (mg/L) Coefficient of variation ( )% Median accuracy (range) ( )%
Enzymatic MPA assay TDM Online 1 0.8 45 0.85 (0.79  0.93)– 4.2% 106.3 (98.8  116.3)–
TDM Online 2 3.5 45 3.54 (3.43  3.71)– 1.8% 101.1 (98.0  106.0)–
TDM Online 3 12.0 45 12.0 (11.38  12.55)– 2.5% 100.0 (94.8  104.6)–
LC-MS/MS TDM Online 1 0.8 44 0.81 (0.69  0.94)– 8.4% 101.3 (86.0  117.4)–
TDM Online 2 3.5 45 3.39 (3.00  3.91)– 7.1% 96.9 (85.7  111.7)–
TDM Online 3 12.0 45 11.60 (10.30  14.30)– 8.6% 96.7 (85.83  119.17)–
Enzymatic MPA assay ChromSystem 1 1.8 68 2.08 (1.80  2.22)– 4.5% 115.6 (100.0  123.3)–
ChromSystem 2 4.86 68 6.22 (5.57  6.59)– 4.1% 128.0 (114.6  135.6)–
LC-MS/MS ChromSystem 1 1.8 68 1.94 (1.56  2.14)– 7.1% 107.8 (86.7  118.9)–
ChromSystem 2 4.86 67 5.16 (4.27  5.77)– 6.5% 106.2 (87.9  118.7)–
Table II
Analysis of blinded control samples from the Mycophenolate International Proficiency Testing Scheme ( ) by the enzymatic MPA assay and LC-MS/MS in parallel.www.bioanalytics.co.uk 
M22A Patient pool M23A Patient pool M30A Spiked sample M30 B Spiked sample M31A Patient Sample M32 B Spiked sample
Enzymatic MPA
assay LC-MS/MS
Enzymatic MPA
assay LC-MS/MS
Enzymatic MPA
assay LC-MS/MS
Enzymatic MPA
assay LC-MS/MS
Enzymatic MPA
assay LC-MS/MS
Enzymatic MPA
assay LC-MS/MS
Number of
replicates
16 16 16 16 16 16 16 16 15 15 15 15
Median (mg/L)
(range)
1.55 (1.45 1.62)– 1.58 (1.34–
1.76)
1.58 (1.50 1.64)– 1.51 (1.30–
1.86)
3.66 (2.60 3.78)– 3.58 (2.92–
3.88)
1.13 (1.06 1.20)– 1.09 (0.90–
1.20)
1.86 (1.80 1.91)– 1.75 (1.58–
1.95)
10.47 (10.08–
14.14)
10.65 (9.23–
11.30)
Mean (mg/L) 1.55 1.57 1.57 1.53 3.59 3.52 1.13 1.06 1.85 1.76 10.89 10.40
CV% 2.8 8.7 2.67 10.7 7.6 9.4 3.8 8.4 1.7 6.0 12.2 6.9
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Table III
Summary of correlation and bias analysis
Population (number of patients) N  samples° Regression equation r Median normalized relative difference (range) ( )%
All (n  64)=
 MPA > 0.4 mg/L # 865 Y  1.070 X  0.002=  * + 0.9839 6.8 ( 21.2; 42.8)−
 0.4 mg/L<MPA<15 mg/L # 818 Y  1.076 X  0.013=  * − 0.9806 7.0 ( 21.2; 42.8)−
p  0.1134 (NS)=
Age
 paediatric  * (N  20)= 96 Y  1.016 X  0.001=  * − 0.9678 1.5 ( 21.2; 26.9)−
 adults (N  44) = 722 Y  1.083 X  0.011=  * + 0.9831 7.7 ( 20.2; 42.8)−
p<0.0001
Transplanted organ
 kidney (N  34) = 694 Y  1.079 X  0.031=  * − 0.9783 6.7 ( 21.2; 42.8)−
 lung (N  10) = § 109 Y  1.045 X  0.048=  * + 0.9898 8.1 ( 14.0; 33.7)−
p  0.2251 (NS)=
Associated IS (N  34 adult renal transplant recipients)=
 tacrolimus (N  10) = 356 Y  1.038 X  0.04=  * + 0.9848 5.4 ( 20.2; 36.6)−
 cyclosporine (N  10) = 233 Y  1.123 X  0.012=  * − 0.9704 10.7 ( 21.2; 42.8)−
 sirolimus (N  14) = 229 Y  1.117 X  0.153=  * − 0.9838 6.9 ( 18.8; 35.3)−
p<0.0001
Post-transplantation period (N  44 adults)=
 early (< 3 months) 344 Y  1.108 X  0.022=  * − 0.9813 9.3 ( 20.2; 42.8)−
 stable (  3 months) ≥ 378 Y  1.064 X  0.001=  * − 0.9848 6.1 ( 20.2; 36.6)−
p 0.0040=
 # As determined using the enzymatic MPA assay
 * All paediatric patients were renal transplant recipients
 § All lung transplant recipients were on tacrolimus
